Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc.
Biotech investors are always looking for the next big thing. That's exactly what they found in Exelixis (NASDAQ: EXEL), which ranked as one of the top biotech stocks of 2016 (and 2015 also). But Exelixis isn't the little biotech ready to hit the big time anymore. Intra-Cellular Therapies (NASDAQ: ITCI) could be, though.
Intra-Cellular Therapies stock has taken investors on a roller coaster ride so far in 2017. Exelixis has continued its winning ways of prior years. Which stock is now the better buy?
Image source: Getty Images.
Source: Fool.com
Exelixis Inc. Stock
€21.52
0.890%
With 21 Buy predictions and not a single Sell prediction Exelixis Inc. is an absolute favorite of our community.
With a target price of 26 € there is a positive potential of 20.82% for Exelixis Inc. compared to the current price of 21.52 €.
